✦ LIBER ✦

Clinical risk–benefit assessment of dopamine agonists

✍ Scribed by J. C. Möller; K. M. Eggert; M. Unger; P. Odin; K. R. Chaudhuri; W. H. Oertel

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

B.3 Risk-benefit assessment of dopamine

✍ W.H. Oertel; C. Möller; M. Unger; K. Eggert 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Benefit/risk assessment in clinical rese

✍ Peter R. Kowey; Ted D. Friehlng; Roger A. Marinchak 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 194 KB

Clinical Pharmacology of Dopamine Agonis

✍ Y. W. Francis Lam 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB

A reassessment of risks and benefits of

✍ Angelo Antonini; Eduardo Tolosa; Yoshikuni Mizuno; Mitsutoshi Yamamoto; Werner H 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 136 KB

Benefit/Risk Assessment of SERM Therapy

✍ JOSEPH P. COSTANTINO 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

Benefit-Risk of Agonist-Antagonist Analg

📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 235 KB